Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-015031

CHIEF SCIENTIFIC OFFICER sold 12,000 shares at an average $21.73 ($260,800)

  • CHIEF SCIENTIFIC OFFICER acquired 12,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2024-05-29 Exercise or conversion : show line 1 in the form 10b5-1 +12,000 $1.12 $13,440 12,000 D
2024-05-29 Sale : show line 2 in the form 10b5-1 −9,877 $21.56 $212,988 2,123 D
2024-05-29 Sale : show line 3 in the form 10b5-1 −2,123 $22.52 $47,813 0 D
Open-market sales · 12,000 sh · avg $21.73 · $260,800

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2024-05-29 Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (right to buy) −12,000 206,550 D
Loading xslF345X05/form4-05312024_080541.xml…